Wegovy Goes Beyond Obesity... Positive Signals in Six Types of Complications Including Asthma

Comprehensive Post-Hoc Analyses Unveiled at ADA 2026

52% Reduction in Sleep Apnea Risk, 42% Decrease in Asthma

Novo Nordisk is expanding the scope of its obesity drug Wegovy (active ingredient: semaglutide) beyond obesity to encompass a broad range of cardiovascular and metabolic diseases. This is part of its “cardio-metabolic platform” strategy, which aims to target multiple complications simultaneously with a single drug. As competition intensifies with Eli Lilly (tirzepatide) in the obesity drug market, expanding indications is emerging as a key strategy to enhance the drug’s value and increase prescription continuity.

According to the industry on June 9, at the American Diabetes Association (ADA) 2026 Annual Scientific Sessions held in New Orleans from June 5 to 8 (local time), Novo Nordisk simultaneously released six post-hoc analyses examining additional effects of semaglutide. Improvement signals were observed across a range of comorbidities associated with obesity, including sleep apnea, asthma, hypertension, and liver health.

Product image of Wegovy, a obesity treatment drug by Novo Nordisk (active ingredient semaglutide). Novo Nordisk

The most notable area was obstructive sleep apnea (OSA). This finding comes from the 'SELECT' clinical trial, which tracked 17,604 overweight and obese adults with cardiovascular disease. In the post-hoc analysis, the group receiving 2.4 mg of semaglutide had a 52% lower risk of developing new sleep apnea compared to the placebo group. The number of new cases was 30 in the semaglutide group and 65 in the placebo group. It is believed that weight loss contributed to alleviating upper airway obstruction.

Significant results were also seen in other respiratory areas. Among 1,190 SELECT participants who self-reported asthma, the risk of asthma-related adverse events decreased by 42%. In addition, the inflammatory marker high-sensitivity C-reactive protein (hsCRP) decreased by 38.9% at week 104. This suggests that semaglutide’s anti-inflammatory effects may operate through a mechanism independent of weight loss.

Consistent improvements were also observed in blood pressure and liver health. In an integrated analysis of 597 patients with uncontrolled hypertension, systolic blood pressure was reduced by 5.48 mmHg and diastolic blood pressure by 2.73 mmHg compared to placebo. In an analysis of 800 patients with metabolic dysfunction-associated steatohepatitis (MASH), cardio-metabolic indicators such as HbA1c, body weight, and triglycerides, as well as liver fibrosis markers, showed consistent improvement over 72 weeks regardless of baseline glucose levels.

The industry is paying close attention to the fact that these data are being accumulated as evidence for future pivotal clinical trials. The strategy of detecting signals in post-hoc analyses and then verifying them in prospective clinical trials to add new indications is a classic approach for extending a drug’s market lifespan and expanding insurance coverage. As the number of indications increases, prescription drop-off rates decrease and bargaining power in drug pricing negotiations strengthens.

Novo Nordisk is not only expanding its single-ingredient drugs but also building a pipeline of next-generation combination drugs. At ADA 2026, Cagrisema—which was also unveiled—reduced HbA1c by 1.91% in phase 3 trials, outperforming semaglutide 2.4 mg (1.75%), and achieved a 14.2% reduction in body weight. Zegnatide (formerly Amycretin), a single molecule incorporating GLP-1 and amylin receptors, achieved a 14.6% reduction in body weight at the highest dose in phase 2 trials.

Andrea Traina, Senior Medical Director for Obesity and Liver Health at Novo Nordisk, said, “These analyses reinforce the clinical evidence for semaglutide not only in obesity but also in cardiovascular disease and MASH.”

This content was produced with the assistance of AI translation services.